Besremi 250 micrograms/0.5 mL solution for injection in pre-filled pen

DRUG2 trials

Sponsors

Aop Orphan Pharmaceuticals GmbH, St. Olavs Hospital HF

Conditions

CHRONIC MYELOID LEUKEMIAEssential Thrombocythaemia

Phase 2

A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM DIAGNOSIS: A RANDOMIZED PROSPECTIVE TRIAL (BosuPeg)

Active, not recruitingCTIS2024-517417-32-00

St. Olavs Hospital HFCHRONIC MYELOID LEUKEMIA

Start: 2018-11-22Target: 164Updated: 2024-11-29

Phase 3

A Phase III, single arm, multicentre study to evaluate the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythaemia patients who are intolerant or refractory to or not eligible for other cytoreductive treatments

Active, not recruitingCTIS2023-505160-12-00

Aop Orphan Pharmaceuticals GmbHEssential Thrombocythaemia

Start: 2023-12-04Target: 132Updated: 2025-09-18

Related Papers

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Blood2024-11-05

ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.

2024-03-0411 citations